F. Hoffmann-La Roche had 52 patents in artificial intelligence during Q4 2023.The patents filed by F. Hoffmann-La Roche Ltd in Q4 2023 cover a range of innovative techniques in the field of healthcare. These include methods for calculating immune context scores in tumor tissue samples to aid in diagnostic and treatment decisions, screening subjects for the risk of chronic kidney disease, using artificial intelligence to predict disease progression and select treatments for spinal muscular atrophy, detecting advanced stages of age-related macular degeneration in retinas, and predicting visual acuity response using imaging data and neural networks. These patents showcase the company’s commitment to advancing medical technologies for improved patient outcomes. GlobalData’s report on F. Hoffmann-La Roche gives a 360-degreee view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights F. Hoffmann-La Roche Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

F. Hoffmann-La Roche grant share with artificial intelligence as a theme is 17% in Q4 2023. Grant share is based on the ratio of number of grants to total number of patents.

Recent Patents

Application: Methods and systems for evaluation of immune cell infiltrate in tumor samples (Patent ID: US20230419489A1)

The patent by F. Hoffmann-La Roche Ltd. describes a method for evaluating tumors by quantifying immune cell markers in tumor tissue samples and applying a non-linear continuous scoring function to generate an immune context score (ICS) indicative of patient outcomes. The ICS can be used for prognostic purposes, such as determining overall survival, disease-specific survival, or progression-free survival, as well as predicting the likelihood of response to specific treatments. The method involves calculating feature metrics for immune cell markers, including CD3 and total lymphocyte counts, within specific regions of interest in the tumor tissue, and integrating these metrics with clinical variables to make diagnostic and treatment decisions.

The patent also includes claims related to the method, such as quantitating total lymphocytes and immune cell markers in different regions of interest within the tumor tissue, applying a non-linear continuous scoring function to generate the ICS, and using the ICS for prognostic purposes by comparing it to predetermined cutoffs or integrating it with clinical variables. The method can be implemented using an image analysis system and computer-executable instructions stored on a non-transitory computer-readable storage medium. Additionally, the patent describes various scenarios for calculating feature vectors, including registering serial sections of tissue samples stained for different immune cell markers and deriving quantitative measures of lymphocytes based on different cell densities and ratios within the regions of interest.

To know more about GlobalData’s detailed insights on F. Hoffmann-La Roche, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.